Replies to post #116140 on Biotech Values

[jq1234]

First of all, some bioequivalence trials include actual patients. Second of all, we dismiss the notion of the requirement coming from FDA at this point because no one disclosed it. The buzz certainly could come from someone exploring efficacy/safety trial of biosimilar Copaxone for EU market because it is required over there.